T0	Limitation 15905 15906	A
T1	Limitation 16075 16082	Because
T2	Limitation 16271 16278	Delayed
T3	Limitation 16431 16434	For
T4	Limitation 16595 16607	Furthermore,
T5	Limitation 16681 16683	We
T6	Limitation 16812 16814	We
T7	Limitation 17068 17070	An
T8	Limitation 17235 17237	We
T9	Limitation 18071 18073	In
T10	FollowUp 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T11	OTHER 16611 16679	do not have complete information about adherence to study medication
T12	OutcomeAssessor 16849 16875	unmasking of investigators
T13	LackOfOutcomeMeasurementData 17071 17233	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed by the modified Rankin Scale
T14	LackOfOutcomeMeasurementData 17238 17404	measured clinical outcome 3 months after haemorrhage, which is a usual period for outcome assessment in stroke studies, and although a benefit might be detected later
T15	OutcomeMeasures 16087 16269	study was pragmatically designed to assess whether magnesium improved clinical outcome after aneurysmal subarachnoid haemorrhage, we chose poor outcome as our primary outcome measure
T16	OutcomeMeasures 16362 16429	did not include delayed cerebral haemorrhage as a secondary outcome
T17	OutcomeMeasures 16455 16498	did not include other baseline measurements
